Index RUT
P/E -
EPS (ttm) -0.34
Insider Own 52.98%
Shs Outstand 773.28M
Perf Week -1.54%
Market Cap 892.15M
Forward P/E -
EPS next Y -0.27
Insider Trans 3.16%
Shs Float 327.73M
Perf Month -0.39%
Income -252.46M
PEG -
EPS next Q -0.10
Inst Own 25.87%
Short Float 26.42%
Perf Quarter 21.90%
Sales 799.60M
P/S 1.12
EPS this Y -49.33%
Inst Trans -3.05%
Short Ratio 10.35
Perf Half Y -4.48%
Book/sh 1.80
P/B 0.71
EPS next Y 27.68%
ROA -12.19%
Short Interest 86.57M
Perf Year -30.05%
Cash/sh 0.11
P/C 11.79
EPS next 5Y 12.00%
ROE -18.00%
52W Range 0.85 - 2.24
Perf YTD -15.23%
Dividend Est. -
P/FCF -
EPS past 5Y 1.56%
ROI -15.43%
52W High -42.86%
Beta 1.74
Dividend TTM -
Quick Ratio 1.62
Sales past 5Y 3.29%
Gross Margin 21.88%
52W Low 50.31%
ATR (14) 0.06
Dividend Ex-Date -
Current Ratio 1.91
EPS Y/Y TTM 13.28%
Oper. Margin -24.90%
RSI (14) 56.05
Volatility 4.51% 4.35%
Employees 3930
Debt/Eq 0.33
Sales Y/Y TTM -12.38%
Profit Margin -31.57%
Recom 1.00
Target Price 4.25
Option/Short Yes / Yes
LT Debt/Eq 0.31
EPS Q/Q -376.54%
Payout -
Rel Volume 0.25
Prev Close 1.26
Sales Surprise -5.08%
EPS Surprise -25.79%
Sales Q/Q -26.89%
Earnings May 07 AMC
Avg Volume 8.37M
Price 1.28
SMA20 2.28%
SMA50 11.81%
SMA200 -5.45%
Trades
Volume 2,103,093
Change 1.59%
Date
Action
Analyst
Rating Change
Price Target Change
Jun-29-23 Upgrade
Barrington Research
Mkt Perform → Outperform
$2
Dec-15-22 Initiated
H.C. Wainwright
Buy
$3
Jan-24-22 Downgrade
Barrington Research
Outperform → Mkt Perform
Jun-21-21 Initiated
Ladenburg Thalmann
Buy
$7
Nov-25-19 Initiated
Piper Jaffray
Overweight
$2.50
Mar-02-18 Downgrade
JP Morgan
Neutral → Underweight
Sep-14-17 Downgrade
JP Morgan
Overweight → Neutral
Jun-21-16 Reiterated
Standpoint Research
Buy
$16 → $18
Jun-03-16 Initiated
Standpoint Research
Buy
$16
Mar-31-16 Reiterated
Barrington Research
Outperform
$17 → $16
Oct-16-15 Initiated
JP Morgan
Overweight
$14
Sep-11-15 Downgrade
Jefferies
Buy → Hold
Mar-03-15 Downgrade
Oppenheimer
Outperform → Perform
May-12-14 Reiterated
Oppenheimer
Outperform
$13 → $12
Mar-14-14 Initiated
Oppenheimer
Outperform
$13
Nov-13-13 Reiterated
Ladenburg Thalmann
Buy
$10 → $14.50
May-30-13 Reiterated
Ladenburg Thalmann
Buy
$8.50 → $10
Oct-22-12 Initiated
Barrington Research
Outperform
$6
Dec-01-11 Reiterated
Ladenburg Thalmann
Buy
$6 → $8.50
Jul-14-11 Initiated
Ladenburg Thalmann
Buy
$6
Show Previous Ratings
May-12-24 03:24PM
May-09-24 09:18AM
May-08-24 11:47AM
06:56AM
(Thomson Reuters StreetEvents)
03:44AM
09:15PM
Loading…
May-07-24 09:15PM
08:30PM
06:09PM
05:30PM
04:38PM
(Associated Press Finance)
04:05PM
May-03-24 08:00AM
Apr-01-24 01:01PM
Mar-28-24 11:08PM
08:00AM
09:57AM
Loading…
Mar-25-24 09:57AM
Mar-20-24 08:00AM
Mar-05-24 08:52AM
Feb-29-24 08:31AM
Feb-28-24 09:31AM
09:02AM
06:18AM
(Thomson Reuters StreetEvents)
Feb-27-24 09:00PM
07:30PM
06:10PM
05:08PM
(Associated Press Finance)
04:43PM
04:05PM
Feb-26-24 09:16AM
Feb-22-24 04:05PM
01:48PM
Loading…
Feb-08-24 01:48PM
Feb-05-24 08:09AM
Jan-22-24 11:48AM
Jan-09-24 04:05PM
Jan-08-24 08:00AM
Jan-04-24 11:31PM
Jan-03-24 05:05PM
Dec-07-23 10:20AM
Dec-06-23 11:30AM
Nov-28-23 07:00AM
Nov-07-23 10:36AM
(Thomson Reuters StreetEvents)
10:29AM
09:19AM
06:45AM
01:00AM
Nov-06-23 07:30PM
05:30PM
(Associated Press Finance)
05:01PM
04:05PM
Nov-02-23 10:00AM
Oct-31-23 08:00AM
Oct-25-23 04:25PM
Oct-12-23 10:50AM
Oct-06-23 12:03PM
Sep-29-23 01:03PM
Sep-28-23 07:36PM
04:08PM
Sep-13-23 01:18PM
Sep-12-23 08:30AM
Aug-28-23 11:56AM
Aug-07-23 01:21PM
Aug-04-23 01:00AM
Aug-03-23 05:55PM
04:48PM
04:05PM
Jul-25-23 04:05PM
Jul-23-23 08:11AM
Jul-12-23 08:25AM
Jun-29-23 03:51PM
11:23AM
09:53AM
08:10AM
Jun-28-23 07:03AM
06:51AM
06:45AM
Jun-08-23 07:11AM
Jun-02-23 11:31AM
May-10-23 06:13AM
May-04-23 12:23PM
05:48AM
(Thomson Reuters StreetEvents)
May-03-23 10:00PM
06:25PM
05:23PM
04:05PM
Apr-25-23 04:05PM
Apr-13-23 07:46AM
Mar-17-23 06:21AM
Mar-14-23 12:08PM
Mar-09-23 03:42PM
08:00AM
Mar-08-23 04:34PM
12:01PM
08:05AM
08:01AM
08:00AM
Feb-26-23 07:13AM
06:40AM
Feb-24-23 10:43AM
07:11AM
(Thomson Reuters StreetEvents)
01:00AM
OPKO Health, Inc. is a biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. It operates through the following segments: Diagnostics and Pharmaceuticals. The Diagnostics segment includes the clinical laboratory operations of BioReference, as well as point-of-care operations. The Pharmaceuticals segment includes pharmaceutical operations in Chile, Mexico, Ireland, Israel, and Spain and pharmaceutical research and development operations. The company was founded in October 1991 and is headquartered in Miami, FL.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
FROST PHILLIP MD ET AL CEO & Chairman Mar 18 '24 Buy 0.87 500,000 437,100 210,968,225 Mar 18 04:45 PM FROST PHILLIP MD ET AL CEO & Chairman Mar 14 '24 Buy 0.89 500,000 444,300 210,468,225 Mar 14 05:00 PM FROST PHILLIP MD ET AL CEO & Chairman Mar 13 '24 Buy 0.93 500,000 463,750 209,968,225 Mar 13 04:44 PM FROST PHILLIP MD ET AL CEO & Chairman Mar 12 '24 Buy 0.93 600,000 559,380 209,468,225 Mar 12 05:27 PM FROST PHILLIP MD ET AL CEO & Chairman Feb 28 '24 Buy 0.99 500,000 496,150 208,868,225 Feb 28 05:31 PM FROST PHILLIP MD ET AL CEO & Chairman Feb 21 '24 Buy 0.99 1,000,000 991,700 208,368,225 Feb 21 05:10 PM FROST PHILLIP MD ET AL CEO & Chairman Feb 07 '24 Buy 0.98 1,500,000 1,462,800 207,368,225 Feb 07 05:09 PM KRASNO RICHARD M Director Jan 29 '24 Buy 0.99 30,000 29,838 103,333 Jan 29 03:30 PM FROST PHILLIP MD ET AL CEO & Chairman Jan 19 '24 Buy 0.98 500,000 488,650 205,868,225 Jan 19 04:54 PM FROST PHILLIP MD ET AL CEO & Chairman Jan 18 '24 Buy 0.97 400,000 386,200 205,368,225 Jan 18 05:06 PM HSIAO JANE PH D Vice Chairman & CTO Jan 17 '24 Buy 0.95 150,000 142,500 27,999,880 Jan 17 05:09 PM FROST PHILLIP MD ET AL CEO & Chairman Jan 16 '24 Buy 0.95 1,000,000 954,300 204,968,225 Jan 16 05:03 PM FROST PHILLIP MD ET AL CEO & Chairman Jan 11 '24 Buy 0.94 511,531 480,379 203,968,225 Jan 11 05:15 PM Nabel Gary J. Chief Innovation Officer Jan 08 '24 Buy 0.93 216,184 200,427 351,442 Jan 10 05:56 PM FROST PHILLIP MD ET AL CEO & Chairman Jan 05 '24 Buy 0.90 1,500,000 1,344,600 203,456,694 Jan 08 08:54 AM Zerhouni Elias A. Vice Chairman and President Jan 05 '24 Buy 0.93 550,300 514,093 20,327,814 Jan 05 05:26 PM HSIAO JANE PH D Vice Chairman & CTO Jan 05 '24 Buy 0.87 150,010 130,899 27,849,880 Jan 08 09:10 AM PFENNIGER RICHARD C JR Director Jan 05 '24 Buy 0.94 25,000 23,429 325,000 Jan 05 12:42 PM PAGANELLI JOHN A Director Jan 05 '24 Buy 0.88 25,000 22,080 384,340 Jan 05 04:00 PM Rubin Steven D Executive VP-Administration Jan 05 '24 Buy 0.87 10,000 8,669 6,187,732 Jan 05 01:39 PM PFENNIGER RICHARD C JR Director Nov 13 '23 Buy 1.30 25,000 32,491 300,000 Nov 14 07:10 AM FROST PHILLIP MD ET AL CEO & Chairman Nov 10 '23 Buy 1.25 500,000 625,462 201,956,694 Nov 13 08:23 AM HSIAO JANE PH D Vice Chairman & CTO Nov 10 '23 Buy 1.27 100,000 126,659 27,699,870 Nov 13 08:21 AM Rubin Steven D Executive VP-Administration Nov 10 '23 Buy 1.30 10,000 13,000 6,177,732 Nov 13 08:21 AM FROST PHILLIP MD ET AL CEO & Chairman Nov 09 '23 Buy 1.28 500,000 641,471 201,456,694 Nov 13 08:23 AM FROST PHILLIP MD ET AL CEO & Chairman Aug 17 '23 Buy 1.76 100,000 175,804 200,956,694 Aug 18 07:10 AM FROST PHILLIP MD ET AL CEO & Chairman Aug 14 '23 Buy 1.75 75,000 131,260 200,856,694 Aug 15 07:05 AM FROST PHILLIP MD ET AL CEO & Chairman Aug 09 '23 Buy 1.82 100,000 181,752 200,781,694 Aug 10 06:59 AM FROST PHILLIP MD ET AL CEO & Chairman Aug 07 '23 Buy 1.84 650,000 1,194,998 200,681,694 Aug 08 07:07 AM
Index -
P/E -
EPS (ttm) -5.25
Insider Own 37.81%
Shs Outstand 25.98M
Perf Week 5.54%
Market Cap 542.61M
Forward P/E -
EPS next Y -0.68
Insider Trans -7.28%
Shs Float 16.26M
Perf Month 85.43%
Income -135.02M
PEG -
EPS next Q -0.48
Inst Own 42.42%
Short Float 7.15%
Perf Quarter 432.05%
Sales 221.85M
P/S 2.45
EPS this Y 65.21%
Inst Trans -11.87%
Short Ratio 2.90
Perf Half Y 1321.23%
Book/sh 7.93
P/B 2.62
EPS next Y 62.29%
ROA -28.73%
Short Interest 1.16M
Perf Year 154.60%
Cash/sh 4.32
P/C 4.81
EPS next 5Y -
ROE -50.41%
52W Range 1.16 - 21.71
Perf YTD 654.55%
Dividend Est. -
P/FCF -
EPS past 5Y -
ROI -41.99%
52W High -4.42%
Beta 2.30
Dividend TTM -
Quick Ratio 2.99
Sales past 5Y 5.08%
Gross Margin 38.95%
52W Low 1688.79%
ATR (14) 1.78
Dividend Ex-Date -
Current Ratio 3.22
EPS Y/Y TTM 88.17%
Oper. Margin -53.62%
RSI (14) 77.15
Volatility 9.03% 12.08%
Employees 1000
Debt/Eq 0.58
Sales Y/Y TTM -0.91%
Profit Margin -60.86%
Recom 2.00
Target Price 15.25
Option/Short Yes / Yes
LT Debt/Eq 0.55
EPS Q/Q 74.45%
Payout -
Rel Volume 2.39
Prev Close 20.32
Sales Surprise 26.23%
EPS Surprise 62.83%
Sales Q/Q 44.70%
Earnings Apr 29 AMC
Avg Volume 401.18K
Price 20.75
SMA20 47.93%
SMA50 84.06%
SMA200 270.58%
Trades
Volume 959,244
Change 2.12%
Apr-30-24 07:31AM
Apr-29-24 08:55PM
05:50PM
04:05PM
Apr-23-24 08:30AM
04:05PM
Loading…
Apr-04-24 04:05PM
Mar-21-24 09:55AM
Mar-14-24 08:30AM
Feb-26-24 04:05PM
Feb-21-24 08:33AM
Feb-20-24 04:26PM
Feb-01-24 04:30PM
Jan-24-24 04:30PM
Jan-08-24 08:55AM
Dec-01-23 08:30AM
04:05PM
Loading…
Nov-28-23 04:05PM
Nov-20-23 04:05PM
Nov-10-23 09:55AM
Nov-05-23 12:10PM
Oct-31-23 08:19AM
(Thomson Reuters StreetEvents) -30.34%
Oct-30-23 06:02PM
04:05PM
Oct-09-23 04:05PM
Sep-22-23 04:05PM
Sep-13-23 01:01PM
Sep-11-23 08:00AM
Sep-06-23 08:00AM
Aug-21-23 07:00AM
Aug-09-23 08:16AM
07:59AM
(Thomson Reuters StreetEvents)
08:05PM
Loading…
Aug-08-23 08:05PM
04:05PM
Aug-07-23 08:00AM
Jul-19-23 07:05AM
Jul-18-23 04:05PM
Jun-28-23 07:00AM
Jun-26-23 04:01PM
Jun-20-23 07:00AM
May-24-23 04:05PM
May-23-23 07:00AM
May-22-23 04:05PM
May-15-23 09:35AM
May-09-23 04:05PM
May-04-23 07:00AM
May-03-23 01:06PM
Apr-28-23 06:39PM
08:10AM
07:04AM
Apr-18-23 04:05PM
12:55PM
Apr-03-23 08:30AM
Mar-22-23 04:36PM
Mar-20-23 09:07PM
08:45AM
Mar-18-23 06:48PM
Mar-16-23 08:45AM
Mar-14-23 04:16PM
Mar-01-23 07:30AM
Feb-28-23 08:30AM
Feb-21-23 04:30PM
Feb-16-23 08:30AM
Jan-31-23 04:15PM
Jan-30-23 08:30AM
Jan-27-23 06:00AM
Jan-26-23 04:53PM
GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. The firm, through its Centrellis health intelligence platform, generates a more complete understanding of disease and wellness and provides science-driven solutions to the most pressing medical needs. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
PFENNIGER RICHARD C JR Director May 02 '24 Option Exercise 0.00 918 0 21,836 May 03 04:04 PM Feeley Kevin CHIEF FINANCIAL OFFICER Apr 29 '24 Option Exercise 0.00 3,013 0 31,940 Apr 30 04:27 PM Stueland Katherine Chief Executive Officer Apr 29 '24 Option Exercise 0.00 15,496 0 82,194 Apr 30 04:30 PM Stueland Katherine Chief Executive Officer Apr 29 '24 Sale 11.04 6,325 69,808 75,869 Apr 30 04:30 PM Feeley Kevin CHIEF FINANCIAL OFFICER Apr 29 '24 Sale 11.04 1,104 12,185 30,836 Apr 30 04:27 PM Stueland Katherine CHIEF EXECUTIVE OFFICER Mar 18 '24 Sale 10.59 8,559 90,661 66,698 Mar 19 04:15 PM Feeley Kevin CHIEF FINANCIAL OFFICER Mar 18 '24 Sale 10.59 3,253 34,455 28,927 Mar 19 04:14 PM Saad Kareem CHIEF TRANSFORMATION OFFICER Mar 18 '24 Sale 10.59 2,008 21,269 29,517 Mar 19 04:14 PM Stueland Katherine CHIEF EXECUTIVE OFFICER Mar 16 '24 Option Exercise 0.00 18,750 0 75,257 Mar 19 04:15 PM Feeley Kevin CHIEF FINANCIAL OFFICER Mar 16 '24 Option Exercise 0.00 7,197 0 32,180 Mar 19 04:14 PM Saad Kareem CHIEF TRANSFORMATION OFFICER Mar 16 '24 Option Exercise 0.00 5,114 0 31,525 Mar 19 04:14 PM Stueland Katherine CHIEF EXECUTIVE OFFICER Mar 12 '24 Sale 9.21 2,618 24,111 56,507 Mar 13 04:24 PM Feeley Kevin CHIEF FINANCIAL OFFICER Mar 12 '24 Sale 9.21 931 8,574 24,983 Mar 13 04:28 PM Saad Kareem CHIEF TRANSFORMATION OFFICER Mar 12 '24 Sale 9.21 897 8,261 26,411 Mar 13 04:22 PM Feeley Kevin CHIEF FINANCIAL OFFICER Mar 09 '24 Option Exercise 0.00 2,462 0 25,914 Mar 12 05:27 PM Stueland Katherine CHIEF EXECUTIVE OFFICER Mar 09 '24 Option Exercise 0.00 6,547 0 59,125 Mar 12 05:26 PM Saad Kareem CHIEF TRANSFORMATION OFFICER Mar 09 '24 Option Exercise 0.00 2,841 0 27,308 Mar 12 05:25 PM Casdin Capital, LLC Director Mar 05 '24 Buy 8.83 900 7,944 2,703,509 Mar 06 07:32 PM Casdin Capital, LLC Director Mar 04 '24 Buy 8.74 40,000 349,708 2,702,609 Mar 06 07:32 PM Saad Kareem CHIEF TRANSFORMATION OFFICER Jan 22 '24 Sale 3.24 193 625 24,467 Jan 23 04:10 PM Saad Kareem CHIEF TRANSFORMATION OFFICER Jan 19 '24 Option Exercise 0.00 546 0 24,660 Jan 23 04:10 PM Saad Kareem Chief Transformation Officer Jan 03 '24 Sale 2.58 105 271 24,114 Jan 04 05:03 PM Saad Kareem Chief Transformation Officer Jan 01 '24 Option Exercise 0.00 273 0 24,219 Jan 03 04:25 PM Ryan Jason Executive Chairman Dec 31 '23 Option Exercise 0.00 67,780 0 73,614 Jan 03 04:23 PM Stueland Katherine Chief Executive Officer Dec 18 '23 Sale 2.16 11,734 25,338 52,578 Dec 19 09:26 PM Feeley Kevin Chief Financial Officer Dec 18 '23 Sale 2.16 2,948 6,366 23,035 Dec 19 09:24 PM Saad Kareem Chief Transformation Officer Dec 18 '23 Sale 2.16 1,700 3,671 23,946 Dec 19 09:25 PM Stueland Katherine Chief Executive Officer Dec 16 '23 Option Exercise 0.00 18,750 0 64,312 Dec 19 09:26 PM Feeley Kevin Chief Financial Officer Dec 16 '23 Option Exercise 0.00 7,197 0 25,983 Dec 19 09:24 PM Saad Kareem Chief Transformation Officer Dec 16 '23 Option Exercise 0.00 5,114 0 25,646 Dec 19 09:25 PM Stueland Katherine Chief Executive Officer Dec 11 '23 Sale 1.61 3,673 5,915 45,562 Dec 12 04:06 PM Feeley Kevin Chief Financial Officer Dec 11 '23 Sale 1.61 908 1,462 18,786 Dec 12 04:04 PM Saad Kareem Chief Transformation Officer Dec 11 '23 Sale 1.61 850 1,369 20,532 Dec 12 04:05 PM Saad Kareem Chief Transformation Officer Dec 09 '23 Option Exercise 0.00 2,841 0 21,382 Dec 12 04:05 PM Stueland Katherine Chief Executive Officer Dec 09 '23 Option Exercise 0.00 6,546 0 49,235 Dec 12 04:06 PM Feeley Kevin Chief Financial Officer Dec 09 '23 Option Exercise 0.00 2,462 0 19,694 Dec 12 04:04 PM Feeley Kevin Chief Financial Officer Dec 04 '23 Sale 1.77 270 478 17,232 Dec 05 04:45 PM Ryan Jason Executive Chairman Nov 17 '23 Buy 1.54 58,000 89,181 114,742 Nov 20 04:32 PM Ryan Jason Executive Chairman Nov 16 '23 Buy 1.27 56,742 72,187 56,742 Nov 20 04:32 PM Meister Keith A. Director Nov 15 '23 Sale 1.29 883,742 1,140,027 3,011,066 Nov 17 04:18 PM PFENNIGER RICHARD C JR Director Nov 08 '23 Buy 1.49 10,000 14,889 20,918 Nov 08 07:19 PM Saad Kareem Chief Transformation Officer Oct 20 '23 Sale 3.44 164 564 18,541 Oct 23 05:52 PM Ryan Jason Executive Chairman Oct 17 '23 Sale 3.19 42 134 5,834 Oct 18 04:59 PM Saad Kareem Chief Transformation Officer Oct 03 '23 Sale 3.56 85 303 18,159 Oct 03 04:19 PM Stueland Katherine Chief Executive Officer Sep 18 '23 Sale 4.16 10,752 44,749 42,689 Sep 19 06:09 PM Feeley Kevin Chief Financial Officer Sep 18 '23 Sale 4.16 2,742 11,409 16,785 Sep 19 06:08 PM Saad Kareem Chief Transformation Officer Sep 18 '23 Sale 4.16 1,580 6,575 17,971 Sep 19 06:08 PM Feeley Kevin Chief Financial Officer Sep 16 '23 Option Exercise 0.00 7,197 0 19,527 Sep 19 06:08 PM Stueland Katherine Chief Executive Officer Sep 11 '23 Sale 4.62 2,675 12,369 34,691 Sep 12 06:42 PM Feeley Kevin Chief Financial Officer Sep 11 '23 Sale 4.62 904 4,180 12,330 Sep 12 06:40 PM Saad Kareem Chief Transformation Officer Sep 11 '23 Sale 4.62 846 3,912 14,437 Sep 12 06:41 PM Feeley Kevin Chief Financial Officer Sep 09 '23 Option Exercise 0.00 2,462 0 13,234 Sep 12 06:40 PM Feeley Kevin Chief Financial Officer Sep 05 '23 Sale 4.38 269 1,178 10,772 Sep 06 04:56 PM PFENNIGER RICHARD C JR Director Aug 17 '23 Buy 5.10 5,000 25,523 10,918 Aug 18 05:10 PM White Karen Ann Chief People Officer Jul 26 '23 Sale 7.41 61 452 4,761 Jul 27 04:12 PM Saad Kareem Chief Transformation Officer Jul 20 '23 Sale 7.85 163 1,280 12,442 Jul 21 09:58 PM Saad Kareem Chief Transformation Officer Jul 03 '23 Sale 5.99 83 497 12,059 Jul 05 05:16 PM White Karen Ann Chief People Officer Jul 03 '23 Sale 5.99 45 270 4,685 Jul 05 05:18 PM Stueland Katherine Chief Executive Officer Jun 20 '23 Sale 6.37 7,965 50,727 30,819 Jun 21 04:05 PM Feeley Kevin Chief Financial Officer Jun 20 '23 Sale 6.37 2,744 17,473 10,324 Jun 21 04:06 PM White Karen Ann Chief People Officer Jun 20 '23 Sale 6.37 1,549 9,865 4,631 Jun 21 04:05 PM Saad Kareem Chief Transformation Officer Jun 20 '23 Sale 6.37 1,221 7,774 11,869 Jun 21 04:04 PM Feeley Kevin Chief Financial Officer Jun 16 '23 Option Exercise 0.00 7,197 0 13,068 Jun 21 04:06 PM Feeley Kevin Chief Financial Officer Jun 13 '23 Sale 6.49 903 5,860 5,871 Jun 13 05:19 PM Stueland Katherine Chief Executive Officer Jun 12 '23 Sale 6.49 2,674 17,354 20,034 Jun 13 05:23 PM Saad Kareem Chief Transformation Officer Jun 12 '23 Sale 6.49 845 5,484 7,976 Jun 13 05:22 PM White Karen Ann Chief People Officer Jun 12 '23 Sale 6.49 828 5,374 2,770 Jun 13 05:25 PM Feeley Kevin Chief Financial Officer Jun 09 '23 Option Exercise 0.00 2,462 0 6,774 Jun 13 05:19 PM Feeley Kevin Chief Financial Officer Jun 02 '23 Sale 7.00 263 1,841 4,312 Jun 05 04:42 PM PFENNIGER RICHARD C JR Director May 18 '23 Buy 5.90 5,000 29,500 5,918 May 22 04:59 PM Stueland Katherine Chief Executive Officer May 16 '23 Sale 6.50 8,685 56,439 16,162 May 18 07:21 PM Feeley Kevin Chief Financial Officer May 16 '23 Sale 6.50 1,516 9,852 3,856 May 18 07:22 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite